Jamieson Wellness Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

 

  Establishes 2022 Guidance and Declares Fourth Quarter Dividend  

 

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its fourth quarter and year ended December 31, 2021. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

 

  Highlights of Fourth Quarter 2021 Results versus Fourth Quarter 2020 Results  

 
  • Revenue increased 7.9% to $129.8 million;
  •  
  • Jamieson Brands revenue increased by 11.2%;
  •  
  • Adjusted EBITDA (1) increased 14.9% to $33.8 million;
  •  
  • Net earnings increased 31.1% to $20.2 million and Adjusted net earnings (1) increased 16.3% to $20.5 million; and
  •  
  • Diluted earnings per share were $0.48, and Adjusted diluted earnings per share (2) increased 16.7% to $0.49.
  •  

  Highlights of Full Year 2021 Results versus Full Year 2020 Results  

 
  • Revenue increased 11.7% to $451.0 million;
  •  
  • Jamieson Brands revenue increased by 8.5%;
  •  
  • Adjusted EBITDA increased 13.8% to $100.1 million;
  •  
  • Net earnings increased 25.2% to $52.1 million and Adjusted net earnings increased 15.2% to $55.2 million; and
  •  
  • Diluted earnings per share were $1.25, and Adjusted diluted earnings per share increased 13.8% to $1.32.
  •  

"We have reached a century of improving the world's health and wellness, and the power of our Jamieson brand continues to resonate strongly with consumers," said Mike Pilato, President and CEO of Jamieson Wellness. "Throughout 2021, we continued to put people first while focusing on operational excellence and leveraging our portfolio of high-quality, innovative products across multiple channels, globally. We closed out the year with another quarter of growth, including an 11% increase in branded revenue and a 15% increase in Adjusted EBITDA. Our market leadership was bolstered by gains in our domestic segment fueling top-line growth, and we saw margin expansion behind increased operating efficiencies. I am thankful to the entire Jamieson Wellness team for delivering another full year of outstanding results as we met many pandemic-related challenges and hit a new milestone of $100 million in Adjusted EBITDA.

 

"As we look to the future and our leadership beyond this 100-year mark, underlying consumer demand for our products remains strong. This, combined with our strategic focus and track record of operational excellence gives us confidence in our ability to continue driving exceptional revenue and earnings growth. We have clear growth targets and recognize that we have a responsibility to achieve them in a way that is sustainable and equitable for our team members, consumers, stakeholders, and communities around the globe. We are extremely proud of the progress and improvements we made in our environmental, social and governance practices in 2021, and of our plans to build on them in 2022 and beyond. Along with the entire team at Jamieson Wellness, I am excited about our ability to impact positive change while delivering on our aggressive but achievable targets, and look forward to solidifying our brand leadership position for the next 100 years."

 

  Fourth Quarter 2021 Results  

 

Revenue increased 7.9% to $129.8 million in the fourth quarter of 2021 compared with $120.4 million in the fourth quarter of 2020 driven by 11.2% growth in Jamieson Brands, partially offset by a 1.9% decline in Strategic Partners.

 

Revenue in the Jamieson Brands segment increased by 11.2% or $10.1 million to $99.8 million. The Company's domestic branded sales increased by 10.9% in the fourth quarter of 2021, with strong point of purchase sales on an expanded consumer base and inventory replenishments to support seasonal promotional activities. The Company's international USD denominated revenue (3) increased by 14.1%, or 12.6% on a reported basis compared with the fourth quarter of 2020 led by continued growth in China, partially offset by strong replenishments earlier in the year to other regions.

 

Revenue in the Strategic Partners segment decreased by 1.9%, or $0.6 million to $30.1 million in the fourth quarter of 2021 reflecting earlier shipments and 37.3% growth realized in the first three quarters to smooth out the timing of production.

 

Gross profit increased by $6.9 million to $49.4 million in the fourth quarter of 2021 mainly driven by revenue growth and improved operating efficiencies. Normalized gross profit margin (2) increased by 150 basis points from 36.6% to 38.1%, reflecting margin improvements in both segments and the mix impact of proportionally higher sales in the Jamieson Brands segment. Normalized gross profit margin in the Jamieson Brands segment increased by 50 basis points from 44.8% to 45.3% due to volume driven efficiencies and cost recoveries, partially offset by ongoing operating costs associated with the Company's new third-party logistics model, elevated costs reflecting ongoing global supply chain challenges, sustained safety measures and increased business continuity costs. Gross profit margin (3) in Strategic Partners increased by 130 basis points from 12.9% to 14.2% mainly due to operational efficiencies.

 

Selling, general and administrative ("SG&A") expenses increased by $0.9 million to $19.5 million in the fourth quarter of 2021. Normalized SG&A expenses (1) increased $1.3 million to $19.3 million in the fourth quarter of 2021 due to additional resources to support strategic initiatives and marketing investments.

 

Earnings from operations increased by $6.1 million, or 27.0%, to $28.9 million in the fourth quarter of 2021 and operating margin (3) increased by 3.3% to 22.2% as a result of higher revenue and gross profit margins, along with lower fixed costs as a percentage of revenue. Normalized earnings from operations (1) increased by $4.2 million, or 16.7% in the fourth quarter of 2021 and normalized operating margin (2) was 22.4% compared with 20.7% in the fourth quarter of 2020.

 

Adjusted EBITDA increased by 14.9% to $33.8 million in the fourth quarter of 2021 and adjusted EBITDA margin (2) was 26.0% compared with 24.4% in the fourth quarter of 2020.

 

Interest expense and other financing costs remained consistent at $1.4 million in the fourth quarter of 2021.

 

Net earnings for the fourth quarter of 2021 was $20.2 million compared with $15.4 million in the fourth quarter of 2020. Adjusted net earnings, which excludes all non-operating expenses and foreign exchange, increased by $2.9 million, or 16.3%, to $20.5 million in the fourth quarter of 2021.

 

Adjusted net earnings excludes costs associated with foreign exchange loss, business integration, COVID-19 related costs, other non-operating earnings or expenses net of related tax effects. A quantitative reconciliation of reported net earnings to EBITDA, Adjusted EBITDA, and non-IFRS Adjusted net earnings is included in the table accompanying this release under the heading "Non-IFRS and Other Financial Measures".

 

  Balance Sheet & Cash Flow  

 

The Company generated $34.3 million in cash from operations during the fourth quarter of 2021 compared with $18.7 million in the fourth quarter of 2020. Cash from operating activities before working capital considerations (1) of $24.5 million was $2.3 million higher due to increased earnings in the current quarter. Cash invested in working capital decreased by $13.3 million driven by favourable timing on the collection of receivables and accelerated inventory purchases realized in previous quarters. The Company's cash as at December 31, 2021 was $6.8 million compared with $1.2 million on December 31, 2020. The Company ended the quarter with approximately $132.7 million in cash and available operating lines and net debt of $142.4 million (1) .

 
                                                                                                                                                                            
   Three months ended      
   December 31      
  ($ in 000's, except as otherwise noted)   

  2021  

 
  

  2020  

 
   $ Change     % Change  
        
Cash, beginning of period  

  9,150  

 
  

  3,144  

 
  

  6,006  

 
  

  191.0%  

 
Cash flows from (used in):        
Operating activities  

34,309

 
  

18,744

 
  

15,565

 
  

83.0%

 
Investing activities  

(5,399)

 
  

(4,220)

 
  

(1,179)

 
  

(27.9%)

 
Financing activities  

(31,285)

 
  

(16,502)

 
  

(14,783)

 
  

(89.6%)

 
  Cash, end of period   

  6,775  

 
  

  1,166  

 
  

  5,609  

 
  

  481.0%  

 
        
Cash flows from operating activities  

34,309

 
  

18,744

 
  

15,565

 
  

83.0%

 
Net Change in non-cash working capital  

(9,799)

 
  

3,464

 
  

(13,263)

 
  

(382.9%)

 
  Cash from operating activities before working capital considerations   

  24,510  

 
  

  22,208  

 
  

  2,302  

 
  

  10.4%  

 
        
        
  ($ in 000's, except as otherwise noted)        As at December 31,
2021
 
   As at December 31,
2020
 
        
  Long-term debt       

  149,125  

 
  

  149,058  

 
Cash      

(6,775)

 
  

(1,166)

 
  Net debt       

  142,350  

 
  

  147,892  

 
        
 

  Fiscal 2022 Outlook  

 

The Company is introducing its outlook for fiscal 2022 and anticipates revenue in a range of $474.0 to $491.0 million, which represents annual growth of 5.0% to 9.0%. The Company estimates Adjusted EBITDA in a range of $108.0 to $112.0 million and Adjusted diluted earnings per share in a range of $1.42 to $1.48.

 

This outlook reflects the following assumptions:

 
  • Jamieson Brands segment revenue growth of 6.0% to 10.0%, driven by the following:
    • Domestic branded revenue growth of 4.0% to 7.0%, reflecting strong consumer demand on a higher post-pandemic baseline and the impact of retail replenishment throughout 2021, and
    •  
    • International branded revenue growth of approximately 20.0% in U.S. dollars, while reported revenues in Canadian dollars may be impacted by foreign exchange volatility.
    •  
  •  
  • Strategic Partners segment revenue growth up to 5.0%.
  •  
  • Normalized SG&A expense increases of 5.0% to 8.0% from increased investments in international markets and our long-term growth opportunities in China.
  •  

  (1) This is a non-IFRS financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS financial measure.
(2) This is a non-IFRS ratio. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS ratio.
(3) This is a supplementary financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each supplementary financial measure.

 

For additional details on the Company's fiscal 2022 outlook, including guidance for the first quarter of 2022, refer to the "Outlook" section in the management's discussion and analysis of financial condition and results of operations ("2021 MD&A") for the three and twelve months ended December 31, 2021.

 

  Declaration of Fourth Quarter Dividend  

 

On February 23, 2022, the board of directors of the Company declared a cash dividend for the fourth quarter of 2021 of $0.15 per common share, or approximately $6.1 million in the aggregate. The dividend will be paid on March 15, 2022 to all common shareholders of record at the close of business on March 4, 2022. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

 

  Board of Directors Transition  

 

Today, the Company is announcing that David Williams, Chair of the Jamieson Wellness Board of Directors, has advised that he will not seek re-election at the Company's 2022 Annual General Meeting ("AGM"). Mr. Williams' retirement from the Board will take effect upon conclusion of the AGM. The Board has appointed Tim Penner to succeed Mr. Williams as Board Chair, following Mr. Penner's election at the AGM. "As Chair of the Board of Directors since the Company's IPO, I am proud of our accomplishments and thankful for the opportunity to contribute to the Company's powerful vision of improving the world's health and wellness. I am confident in Mr. Penner's ability to lead the Board and work with management and the entire Jamieson team to continue the Company's remarkable growth story."

 

  Consolidated Financial Statements and Management's Discussion and Analysis  

 

The Company's audited consolidated annual financial statements and accompanying notes as at and for the three and twelve months ended December 31, 2021 and related 2021 MD&A are available under the Company's profile on SEDAR at www.sedar.com and on the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com .

 

  Conference Call  

 

Management will host a conference call to discuss the Company's fourth quarter and full year 2021 results at 5:00 p.m. ET today, February 24, 2022. The call can be accessed live over the telephone by dialing 1-888-204-4368 from Canada and the U.S. or 1-323-994-2093 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 5102700 and it will be available until Thursday, March 10, 2022.

 

Interested parties may listen to a simultaneous webcast of the conference call by logging on via the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1525514&tp_key=3e3ea4e1b3 . A replay of the webcast will be available for approximately 30 days following the call.

 

  About Jamieson Wellness  

 

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions, the #1 women's natural health focused brand in Canada. For more information, please visit jamiesonwellness.com .

 

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

 

  Forward-Looking Information  

 

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2022 revenue, Adjusted EBITDA and Adjusted diluted earnings per share. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 30, 2021 and under the "Risk Factors" section in the 2021 MD&A filed today, February 24, 2022. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

 

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the 2021 MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 
                                                                                                                                                                                                                                                                                                   
 
 

  Jamieson Wellness Inc.
Selected Consolidated Financial Information
In thousands of Canadian dollars, except share and per share amounts

 
 
 
   Three months ended     Twelve months ended  
   December 31     December 31  
  

  2021  

 
  

  2020  

 
  

  2021  

 
  

  2020  

 
        
  Revenue   

  129,838  

 
  

  120,369  

 
  

  451,032  

 
  

  403,661  

 
Cost of sales  

80,422

 
  

77,855

 
  

288,591

 
  

258,905

 
Gross profit  

49,416

 
  

42,514

 
  

162,441

 
  

144,756

 
        
  Gross profit margin   

  38.1%  

 
  

  35.3%  

 
  

  36.0%  

 
  

  35.9%  

 
        
Selling, general and administrative expenses  

19,521

 
  

18,624

 
  

80,739

 
  

76,259

 
Share-based compensation  

1,021

 
  

1,156

 
  

5,672

 
  

4,925

 
  Earnings from operations   

  28,874  

 
  

  22,734  

 
  

  76,030  

 
  

  63,572  

 
        
  Operating margin   

  22.2%  

 
  

  18.9%  

 
  

  16.9%  

 
  

  15.7%  

 
        
Foreign exchange loss (gain)  

352

 
  

632

 
  

(92)

 
  

460

 
Other expenses  

-

 
  

19

 
  

-

 
  

22

 
Interest expense and other financing costs  

1,366

 
  

1,409

 
  

5,657

 
  

6,042

 
Income before income taxes  

27,156

 
  

20,674

 
  

70,465

 
  

57,048

 
Provision for income taxes  

6,966

 
  

5,269

 
  

18,383

 
  

15,450

 
  Net earnings   

  20,190  

 
  

  15,405  

 
  

  52,082  

 
  

  41,598  

 
  Adjusted net earnings   

  20,489  

 
  

  17,614  

 
  

  55,217  

 
  

  47,948  

 
        
  EBITDA (1)   

  32,225  

 
  

  25,417  

 
  

  90,396  

 
  

  75,299  

 
  Adjusted EBITDA   

  33,771  

 
  

  29,383  

 
  

  100,096  

 
  

  87,985  

 
        
  Adjusted EBITDA margin   

  26.0%  

 
  

  24.4%  

 
  

  22.2%  

 
  

  21.8%  

 
        
  Weighted average number of shares         
Basic  

40,371,018

 
  

39,866,189

 
  

40,150,724

 
  

39,539,955

 
Diluted  

41,921,765

 
  

41,487,349

 
  

41,680,934

 
  

41,160,341

 
        
  Earnings per share attributable to common shareholders:         
Basic, earnings per share  

  0.50  

 
  

  0.39  

 
  

  1.30  

 
  

  1.05  

 
Diluted, earnings per share  

  0.48  

 
  

  0.37  

 
  

  1.25  

 
  

  1.01  

 
Adjusted diluted, earnings per share  

  0.49  

 
  

  0.42  

 
  

  1.32  

 
  

  1.16  

 
 

(1) This is a non-IFRS financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS financial measure.

 
                                                                                                                                                                                                                                                                                         
  
 

  Jamieson Wellness Inc.
Consolidated Statements of Financial Position
In thousands of Canadian dollars

 
 
  
  
     December 31,
2021
 
   December 31,
2020
 
 
  Assets        
  Current assets        
Cash    

6,775

 
  

1,166

 
 
Accounts receivable    

104,186

 
  

97,951

 
 
Inventories    

119,006

 
  

102,645

 
 
Derivatives    

2,149

 
  

-

 
 
Prepaid expenses and other current assets    

5,029

 
  

2,389

 
 
    

  237,145  

 
  

  204,151  

 
 
  Non-current assets        
Property, plant and equipment    

96,977

 
  

83,796

 
 
Goodwill    

122,975

 
  

122,975

 
 
Intangible assets    

192,676

 
  

196,158

 
 
Deferred income tax    

2,702

 
  

2,261

 
 
  Total assets     

  652,475  

 
  

  609,341  

 
 
       
  Liabilities        
  Current liabilities        
Accounts payable and accrued liabilities    

74,533

 
  

73,084

 
 
Income taxes payable    

2,896

 
  

6,580

 
 
Derivatives    

3,317

 
  

8,231

 
 
Current portion of other long-term liabilities    

2,876

 
  

3,115

 
 
    

  83,622  

 
  

  91,010  

 
 
  Long-term liabilities        
Long-term debt    

149,125

 
  

149,058

 
 
Post-retirement benefits    

3,544

 
  

3,538

 
 
Deferred income tax    

53,291

 
  

51,479

 
 
Other long-term liabilities    

20,872

 
  

21,854

 
 
  Total liabilities     

  310,454  

 
  

  316,939  

 
 
       
  Shareholders' equity        
Share capital    

268,214

 
  

255,795

 
 
Contributed surplus    

14,786

 
  

12,986

 
 
Retained earnings    

58,998

 
  

29,023

 
 
Accumulated other comprehensive income (loss)    

23

 
  

(5,402)

 
 
  Total shareholders' equity     

  342,021  

 
  

  292,402  

 
 
  Total liabilities and shareholders' equity     

  652,475  

 
  

  609,341  

 
 
       
       
 

  Jamieson Wellness Inc.
Segment Information
In thousands of Canadian dollars, except as otherwise noted

 

  Jamieson Brands  

 
                                                                                                                                                                                                                                                                                            
     Three months ended
December 31
 
     
    

  2021  

 
  

  2020  

 
   $ Change     % Change   
           
Revenue    

99,784

 
  

89,733

 
  

10,051

 
  

11.2%

 
 
           
Gross profit    

45,157

 
  

38,566

 
  

6,591

 
  

17.1%

 
 
Gross profit margin    

45.3%

 
  

43.0%

 
  

-

 
  

2.3%

 
 
           
Normalized gross profit (1)    

45,157

 
  

40,157

 
  

5,000

 
  

12.5%

 
 
Normalized gross profit margin    

45.3%

 
  

44.8%

 
  

-

 
  

0.5%

 
 
           
Selling, general and administrative expenses    

17,905

 
  

16,906

 
  

999

 
  

5.9%

 
 
Normalized selling, general and administrative expenses    

17,781

 
  

16,369

 
  

1,412

 
  

8.6%

 
 
           
Share-based compensation    

1,021

 
  

1,156

 
  

(135)

 
  

(11.7%)

 
 
           
  Earnings from operations     

  26,231  

 
  

  20,504  

 
  

  5,727  

 
  

  27.9%  

 
 
  Operating margin     

  26.3%  

 
  

  22.9%  

 
  

  -  

 
  

  3.4%  

 
 
           
  Normalized earnings from operations     

  26,355  

 
  

  22,649  

 
  

  3,706  

 
  

  16.4%  

 
 
  Normalized operating margin     

  26.4%  

 
  

  25.2%  

 
  

  -  

 
  

  1.2%  

 
 
           
  Adjusted EBITDA     

  30,468  

 
  

  26,642  

 
  

  3,826  

 
  

  14.4%  

 
 
  Adjusted EBITDA margin     

  30.5%  

 
  

  29.7%  

 
  

  -  

 
  

  0.8%  

 
 
           
           
 

  Strategic Partners  

 
                                                                                                                                                                                                      
     Three months ended
December 31
 
    
    

  2021  

 
  

  2020  

 
   $ Change     % Change  
          
Revenue    

30,054

 
  

30,636

 
  

(582)

 
  

(1.9%)

 
          
Gross profit    

4,259

 
  

3,948

 
  

311

 
  

7.9%

 
Gross profit margin    

14.2%

 
  

12.9%

 
  

-

 
  

1.3%

 
          
Selling, general and administrative expenses    

1,616

 
  

1,718

 
  

(102)

 
  

(5.9%)

 
Normalized selling, general and administrative expenses    

1,567

 
  

1,685

 
  

(118)

 
  

(7.0%)

 
          
  Earnings from operations     

  2,643  

 
  

  2,230  

 
  

  413  

 
  

  18.5%  

 
  Operating margin     

  8.8%  

 
  

  7.3%  

 
  

  -  

 
  

  1.5%  

 
          
  Normalized earnings from operations     

  2,692  

 
  

  2,246  

 
  

  446  

 
  

  19.8%  

 
  Normalized operating margin     

  9.0%  

 
  

  7.3%  

 
  

  -  

 
  

  1.7%  

 
          
  Adjusted EBITDA     

  3,303  

 
  

  2,741  

 
  

  562  

 
  

  20.5%  

 
  Adjusted EBITDA margin     

  11.0%  

 
  

  8.9%  

 
  

  -  

 
  

  2.1%  

 
          
 

(1) This is a non-IFRS financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS financial measure.

 

  Jamieson Brands  

 
                                                                                                                                                                                                                                                        
     Twelve months ended
December 31
 
    
    

  2021  

 
  

  2020  

 
   $ Change     % Change  
          
Revenue    

343,245

 
  

316,423

 
  

26,822

 
  

8.5%

 
          
Gross profit    

148,371

 
  

133,861

 
  

14,510

 
  

10.8%

 
Gross profit margin    

43.2%

 
  

42.3%

 
  

-

 
  

0.9%

 
          
Normalized gross profit    

149,024

 
  

135,452

 
  

13,572

 
  

10.0%

 
Normalized gross profit margin    

43.4%

 
  

42.8%

 
  

-

 
  

0.6%

 
          
Selling, general and administrative expenses    

74,056

 
  

67,169

 
  

6,887

 
  

10.3%

 
Normalized selling, general and administrative expenses    

70,854

 
  

64,227

 
  

6,627

 
  

10.3%

 
          
Share-based compensation    

5,672

 
  

4,925

 
  

747

 
  

15.2%

 
          
  Earnings from operations     

  68,643  

 
  

  61,767  

 
  

  6,876  

 
  

  11.1%  

 
  Operating margin     

  20.0%  

 
  

  19.5%  

 
  

  -  

 
  

  0.5%  

 
          
  Normalized earnings from operations     

  73,412  

 
  

  66,300  

 
  

  7,112  

 
  

  10.7%  

 
  Normalized operating margin     

  21.4%  

 
  

  21.0%  

 
  

  -  

 
  

  0.4%  

 
          
  Adjusted EBITDA     

  90,301  

 
  

  81,519  

 
  

  8,782  

 
  

  10.8%  

 
  Adjusted EBITDA margin     

  26.3%  

 
  

  25.8%  

 
  

  -  

 
  

  0.5%  

 
          
 

  Strategic Partners  

 
                                                                                                                                                                                                      
     Twelve months ended
December 31
 
    
    

  2021  

 
  

  2020  

 
   $ Change     % Change  
          
Revenue    

107,787

 
  

87,238

 
  

20,549

 
  

23.6%

 
          
Gross profit    

14,070

 
  

10,895

 
  

3,175

 
  

29.1%

 
Gross profit margin    

13.1%

 
  

12.5%

 
  

-

 
  

0.6%

 
          
Selling, general and administrative expenses    

6,683

 
  

9,090

 
  

(2,407)

 
  

(26.5%)

 
Normalized selling, general and administrative expenses    

6,417

 
  

6,344

 
  

73

 
  

1.1%

 
          
  Earnings from operations     

  7,387  

 
  

  1,805  

 
  

  5,582  

 
  

  309.3%  

 
  Operating margin     

  6.9%  

 
  

  2.1%  

 
  

  -  

 
  

  4.8%  

 
          
  Normalized earnings from operations     

  7,653  

 
  

  4,551  

 
  

  3,102  

 
  

  68.2%  

 
  Normalized operating margin     

  7.1%  

 
  

  5.2%  

 
  

  -  

 
  

  1.9%  

 
          
  Adjusted EBITDA     

  9,795  

 
  

  6,466  

 
  

  3,329  

 
  

  51.5%  

 
  Adjusted EBITDA margin     

  9.1%  

 
  

  7.4%  

 
  

  -  

 
  

  1.7%  

 
          
 

  Non-IFRS and Other Financial Measures  

 

This press release makes reference to certain financial measures, including non-IFRS financial measures that are historical, non-IFRS measures that are forward-looking, non-GAAP ratios and supplementary financial measures. Management uses these financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. The Company uses the following non‑IFRS financial measures: "EBITDA", "Adjusted EBITDA" and "Adjusted net earnings", the most directly comparable financial measure for each that is disclosed in its financial statements being net earnings, "normalized gross profit", "normalized SG&A", "normalized earnings from operations", "cash from operating activities before working capital considerations" and "net debt", the most directly comparable financial measures for each that is disclosed in its financial statements being gross profit, SG&A, earnings from operations, cash flows from operating activities, and long-term debt, respectively, the following non-IFRS ratios: "Adjusted EBITDA margin", "Adjusted diluted earnings per share", "normalized gross profit margin", "normalized operating margin", and the following supplementary financial measures: "gross profit margin", "operating margin" and "USD denominated revenue", to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non‑IFRS and supplementary financial measures in order to prepare annual operating budgets and to determine components of management compensation. For an explanation of the composition of each such measure and the usefulness and additional uses of each by management, see the " How we Assess the Performance of our Business " section of the 2021 MD&A, which is incorporated by reference. See below for a quantitative reconciliation of each non-IFRS financial measure to its most directly comparable financial measure disclosed in the Company's financial statements to which the measure relates.

 

The following tables provide a quantitative reconciliation of net earnings to EBITDA, Adjusted EBITDA, and Adjusted net earnings, as well as gross profit to normalized gross profit, SG&A to normalized SG&A, earnings from operations to normalized earnings from operations, each of which are non-IFRS financial measures (see the " Non-IFRS and Other Financial Measures " of this press release for further information on each non-IFRS financial measure) for the year ended December 31, 2021 and December 31, 2020.

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
 

  Reconciliation of Non-IFRS Financial Measures
In thousands of Canadian dollars

 
 
 
     Three months ended     Twelve months ended  
     December 31     December 31  
    

  2021  

 
  

  2020  

 
  

  2021  

 
  

  2020  

 
          
  Net earnings     

  20,190  

 
  

  15,405  

 
  

  52,082  

 
  

  41,598  

 
  Add:           
Provision for income taxes    

6,966

 
  

5,269

 
  

18,383

 
  

15,450

 
Interest expense and other financing costs    

1,366

 
  

1,409

 
  

5,657

 
  

6,042

 
Depreciation of property, plant, and equipment    

2,629

 
  

2,336

 
  

10,006

 
  

8,260

 
Amortization of intangible assets    

1,074

 
  

998

 
  

4,268

 
  

3,949

 
          
  Earnings before interest, taxes, depreciation, and amortization (EBITDA)     

  32,225  

 
  

  25,417  

 
  

  90,396  

 
  

  75,299  

 
  Add EBITDA adjustments:           
Share-based compensation (1)    

1,021

 
  

1,156

 
  

5,672

 
  

4,925

 
Foreign exchange loss (gain)    

352

 
  

632

 
  

(92)

 
  

460

 
International market expansion    

-

 
  

-

 
  

-

 
  

13

 
Business integration (2)    

63

 
  

1,759

 
  

1,852

 
  

2,202

 
COVID-19 related costs (3)    

72

 
  

402

 
  

2,409

 
  

5,064

 
Other (4)    

38

 
  

17

 
  

(141)

 
  

22

 
  Adjusted EBITDA     

  33,771  

 
  

  29,383  

 
  

  100,096  

 
  

  87,985  

 
Provision for income taxes    

(6,966)

 
  

(5,269)

 
  

(18,383)

 
  

(15,450)

 
Interest expense and other financing costs    

(1,366)

 
  

(1,409)

 
  

(5,657)

 
  

(6,042)

 
Depreciation of property, plant, and equipment    

(2,629)

 
  

(2,336)

 
  

(10,006)

 
  

(8,260)

 
Amortization of intangible assets    

(1,074)

 
  

(998)

 
  

(4,268)

 
  

(3,949)

 
Share-based compensation (5)    

(1,108)

 
  

(1,012)

 
  

(5,497)

 
  

(4,349)

 
Other    

-

 
  

-

 
  

-

 
  

97

 
Tax effect of normalization adjustments    

(139)

 
  

(745)

 
  

(1,068)

 
  

(2,084)

 
  Adjusted net earnings     

  20,489  

 
  

  17,614  

 
  

  55,217  

 
  

  47,948  

 
          
          
     Three months ended     Twelve months ended  
     December 31     December 31  
    

  2021  

 
  

  2020  

 
  

  2021  

 
  

  2020  

 
          
  Gross profit     

  49,416  

 
  

  42,514  

 
  

  162,441  

 
  

  144,756  

 
Business integration (2)    

-

 
  

1,472

 
  

653

 
  

1,472

 
COVID-19 related costs (3)    

-

 
  

119

 
  

-

 
  

119

 
  Normalized gross profit     

  49,416  

 
  

  44,105  

 
  

  163,094  

 
  

  146,347  

 
  Normalized gross profit margin     

  38.1%  

 
  

  36.6%  

 
  

  36.2%  

 
  

  36.3%  

 
          
  Selling, general and administrative expenses     

  19,521  

 
  

  18,624  

 
  

  80,739  

 
  

  76,259  

 
Business integration (2)    

(63)

 
  

(287)

 
  

(1,200)

 
  

(730)

 
COVID-19 related costs (3)    

(72)

 
  

(283)

 
  

(2,409)

 
  

(4,945)

 
International market expansion    

-

 
  

-

 
  

-

 
  

(13)

 
Other (4)    

(38)

 
  

-

 
  

141

 
  

-

 
  Normalized selling, general and administrative expenses     

  19,348  

 
  

  18,054  

 
  

  77,271  

 
  

  70,571  

 
          
  Earnings from operations     

  28,874  

 
  

  22,734  

 
  

  76,030  

 
  

  63,572  

 
Business integration (2)    

63

 
  

1,759

 
  

1,853

 
  

2,202

 
COVID-19 related costs (3)    

72

 
  

402

 
  

2,409

 
  

5,064

 
International market expansion    

-

 
  

-

 
  

-

 
  

13

 
Share-based compensation (6)    

-

 
  

-

 
  

914

 
  

-

 
Other (4)    

38

 
  

-

 
  

(141)

 
  

-

 
  Normalized earnings from operations     

  29,047  

 
  

  24,895  

 
  

  81,065  

 
  

  70,851  

 
  Normalized operating margin     

  22.4%  

 
  

  20.7%  

 
  

  18.0%  

 
  

  17.6%  

 
          
 
                                 
(1)   

The Company's share-based compensation expense pertains to its long-term incentive plan (the "LTIP"), with performance-based share units ("PSUs"), time-based restricted share units ("RSUs"), and deferred share units expenses, along with associated payroll taxes. Full year 2021 includes a one-time impact of $0.9 million in the first quarter of 2021 relating to the acceleration of share-based compensation expense from future years in relation to the Company's CEO transition. Please refer to Note 16 in the Company's audited consolidated annual financial statements.

 
   

 

 
(2)   

Expenses in the fourth quarter of 2021 relate to system implementation costs while full year 2021 expenses mostly relate to start-up costs to complete the Company's transition to a third-party logistics model to make room for capacity expansion at its Twin Oaks and Scarborough distribution facilities. Prior year expenses included start-up costs of $1.5 million in the aforementioned third-party logistics transition. Remaining expenses pertained to the integration of the Company's operations and supply chain activities, along with a pre-existing contractual obligation, associated with the acquisition and subsequent integration of its acquired business, which terminated at the end of 2020.

 
   

 

 
(3)   

The Company incurred costs related to COVID-19. These costs do not reflect the ongoing costs of operation and they have been adjusted for comparison purposes. The fourth quarter of 2021 includes costs primarily associated with additional safety measures at the Company's operating facilities, including the use of rapid testing to detect and prevent the risk of COVID-19 spread in its manufacturing facilities while full year 2021 also included shift premiums to essential Jamieson hourly staff who maintained production during government lockdowns, a voluntary two-week closure of its Scarborough facility to minimize the risk of COVID-19 spread in the second quarter of 2021, and donations of vitamins and supplements to charitable organizations.

 
   

 

 
(4)   

Full year 2021 consists primarily of a litigation settlement.

 
   

 

 
(5)   

Costs pertaining to the Company's LTIP, net of $0.1 million in tax benefits realized on the vesting of certain share-based awards for the fourth quarter of 2021. Full year 2021 excludes PSUs and RSUs granted to certain employees, and the acceleration of $0.9 million of share-based compensation expense from future years in relation to the Company's CEO transition, net of $1.0 million in tax benefits realized on the vesting of certain share-based awards.

 
   

 

 
(6)   

Full year 2021 includes a one-time impact of $0.9 million in the first quarter of 2021 relating to the acceleration of share-based compensation expense from future years in relation to the Company's CEO transition. Please refer to Note 16 in the Company's audited consolidated annual financial statements.

 
 

 

 

  

  

  Investor and Media Contact Information:  
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com  

 

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×